非小细胞肺癌个体化治疗的困境与希望

Dilemma and prospect of personalized therapy in non.small ＇cell lung cancer

个体化治疗已经成为提高肺癌治疗疗效的希望所在。目前在此方面已经取得一些进展，但非常有限。文章从基于病理组织学类型选择治疗方案的局限性、一线酪氨酸激酶抑制剂（TKI）治疗失败后未定的后续治疗、维持治疗研究中挥之不去的阴影、外周血表皮生长因子受体（EGFR）突变检测在指导TKI治疗选择方面是组织标本的替代抑或陷阱等几方面论述了个体化治疗的困境与希望。

Personalized therapy has became a main method to break through efficacy of chemotherapy in lung cancer. At present, we have got a few progressions in personalized therapy, but which are very -limited. This review discourses upon the dilemma and hope of individualized treatment from the following ways ：limitation of based on histology type to determine treatment regimens, undecided sequential therapy after failure of TKI as front-line therapy for advanced NSCLC patients with EGFR mutation, clinical study of maintenance therapy and EGFR mutation detection based on peripheral blood being trap or surrogate for tumor tissue to direct personalized TKI therapy.